Devonian Reports Additional Molecular Data from MASH Liver Study
Devonian Health Group announced the availability of additional molecular data from a preclinical study using a MASH (metabolic dysfunction–associated steatohepatitis) liver disease model.
DEVONIAN REPORTS ADDITIONAL MOLECULAR DATA FROM MASH LIVER STUDY – DEVONIAN HEALTH GROUP INC.
In this study, the STAM™ mouse model was used to evaluate the effects of the orally administered small-molecule compound Thykamine™. Molecular analyses of liver tissue showed significant downregulation of multiple inflammation- and fibrosis-related genes following treatment, supporting the anti-inflammatory and anti-fibrotic activity of Thykamine™ at the molecular level.
These findings further strengthen previously reported pathological improvements and highlight the therapeutic potential of Thykamine™ for MASH and other inflammatory diseases.